Next Article in Journal
Anti-Inflammatory, Antidiabetic, and Antioxidant Properties of Extracts Prepared from Pinot Noir Grape Marc, Free and Incorporated in Porous Silica-Based Supports
Previous Article in Journal
Insights into the Versatility of Using Atomic Absorption Spectrometry in Antibacterial Research
Previous Article in Special Issue
Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 13
10.3390/molecules29133121
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Agonists and Inhibitors of the cGAS-STING Pathway

by
Xiaoxuan Yu
1,2,*,†,
Linxiang Cai
3,†,
Jingyue Yao
4,†,
Cenming Li
1 and
Xiaoyong Wang
2,*
1
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
2
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China
3
State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China
4
Department of Pharmacy, Fourth Military Medical University, Xi’an 710032, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2024, 29(13), 3121; https://doi.org/10.3390/molecules29133121 (registering DOI)
Submission received: 31 May 2024 / Revised: 24 June 2024 / Accepted: 24 June 2024 / Published: 30 June 2024
(This article belongs to the Special Issue Chemical Biology in Asia)
Browse Figures
Versions Notes

Abstract

:
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is pivotal in immunotherapy. Several agonists and inhibitors of the cGAS-STING pathway have been developed and evaluated for the treatment of various diseases. The agonists aim to activate STING, with cyclic dinucleotides (CDNs) being the most common, while the inhibitors aim to block the enzymatic activity or DNA binding ability of cGAS. Meanwhile, non-CDN compounds and cGAS agonists are also gaining attention. The omnipresence of the cGAS-STING pathway in vivo indicates that its overactivation could lead to undesired inflammatory responses and autoimmune diseases, which underscores the necessity of developing both agonists and inhibitors of the cGAS-STING pathway. This review describes the molecular traits and roles of the cGAS-STING pathway and summarizes the development of cGAS-STING agonists and inhibitors. The information is supposed to be conducive to the design of novel drugs for targeting the cGAS-STING pathway.

1. Introduction

Chemotherapy, surgery, and radiation therapy are three major treatments for cancers. In recent years, immunotherapy is emerging as another treatment for cancers. Generally, chemotherapy eliminates cancers by direct cytotoxic effects; however, it often encounters drug resistance and toxic side effects. By contrast, immunotherapy aims to regulate immunological responses through activating the immune defense system or reshaping the tumor microenvironment (TME). Many chemotherapeutics can cause cellular DNA damages, which may initiate innate immunity to kill cancer cells. Cyclic GMP-AMP synthase (cGAS) is an intracellular detector in the innate immune system that recognizes double-stranded DNA (dsDNA). It converts ATP and GTP into a signaling molecule cyclic GMP-AMP (cGAMP), which then serves as a second messenger to activate the stimulator of interferon genes (STING) protein and trigger the production of interferons in immune responses [1,2]. Mammalian cellular DNA is mainly localized within the nucleus or mitochondria, with only a minimal amount presenting in the cytoplasm, which keeps cGAS in an inactive state [3,4]. During drug treatment, cGAS is activated in a sequence-independent manner upon binding to abnormal dsDNA to produce cGAMP and transmit signals from upstream cells to downstream adaptor proteins. It binds to the C-terminus of the STING protein, facilitating its transport from the endoplasmic reticulum (ER) to the Golgi apparatus by high-order oligomerization and tetramer formation [5]. Once localized to the Golgi apparatus, the STING protein undergoes post-translational palmitoylation at two cysteine residues (Cys88/Cys91) in the N-terminal domain, inducing conformational changes and oligomerization [3]. The STING is primarily expressed in the ER and translocates to the Golgi apparatus upon activation, recruiting TANK-binding kinase 1 (TBK1) and IκB kinase (IKK), which undergo autophosphorylation [6]. The phosphorylated TBK1 and IKK stimulate the transcription factors interferon nuclear factor κB (NF-κB) and interferon regulatory factor 3 (IRF3), eliciting the expression of proinflammatory cytokines such as interleukin 6 (IL-6) and type I interferons (IFN-I) to kill cancer cells [7,8]. The action of an agonist or inhibitor on the cGAS-STING pathway is schematized in Figure 1.
Immune evasion is one of the key features of tumor. Activating antitumor immunity is an effective method against tumors [9]. Activation of the cGAS-STING pathway triggers a strong antitumor immune response by inducing a robust production of IFN-I, which is crucial for activating immune cells, particularly CD8+ T cells [10,11]. As main effector cells for tumor immune surveillance and clearance, CD8+ T cells recognize tumor antigens presented by antigen-presenting cells (APCs) such as dendritic cells (DCs) through the major histocompatibility complex class I (MHC-I), leading to the killing of cancer cells [10]. In APCs, particularly in tumor-resident DCs, the activation of the cGAS-STING pathway lays the basis for the activation and proliferation of T cells, leading to the infiltration of CD8+ T cells and the initiation of immune responses against tumors [12]. Additionally, IFN-I reduces the acidification rate of endo-lysosomes in DCs, prolonging the storage and binding time of tumor antigens and MHC-I molecules in the endosomal compartments, assisting DCs in antigen presentation to CD8+ T cells [13]. T cell infiltration is a hallmark of IFN-I production and is associated with a positive overall prognosis of tumor patients. It has been demonstrated that after immunogenic tumor transplantation into syngeneic mice, STING-deficient mice exhibited faster tumor growth compared to the wild-type mice [14].
In the TME, activation of the cGAS-STING pathway mediates the activity of immune cells, including the maturation of DCs, cross-priming of tumor-related antigens, and cytotoxic T-lymphocytes [15,16]. Natural killer (NK) cells, as a type of cytotoxic lymphocyte, recognize tumor cells lacking MHC class molecules [17]. The cGAS-STING pathway can enhance the antitumor immune surveillance and clearance functions mediated by NK cells. The tumor-derived 2′3′-cGAMP promotes the expression of T cell transcription factor 1 (TCF-1) in NK cells, which are characterized by immune memory features, thereby expanding the number of TCF-1+ NK cells to enhance the tumor-killing ability. Furthermore, 2′3′-cGAMP induces IFN-I to upregulate IL-15 expression in the TME, leading to the increase of IL-15 receptors on DCs and NK cells, and hence enhancing the antitumor activity of NK cells [18,19]. Activation of the cGAS-STING pathway in tumors may induce the expression of immune checkpoint molecules, suppressing the recognition and killing of tumor cells by immune ones [20]. cGAS is essential for the antitumor effect of the immune checkpoint blockade [21], and STING agonist-formulated vaccines can cure tumors resistant to the PD-1 blockade [22]. STING agonists induce the expression of PD-L1 on the surface of tumor cells, thereby inhibiting specific killing of tumor antigens, providing a rationale for the combined use of STING agonists with PD-1/PD-L1 antibodies in tumor immunotherapy [21,22]. The above findings signify that the cGAS-STING pathway plays a vital role in antitumor immunity.
On the other hand, STING also shows a pro-tumorigenic effect in some cases [23]. A pan-cancer analysis revealed that high activation of the cGAS-STING pathway and its downstream signaling components such as TBK1 and IRF3 is associated with reduced immune cell infiltration in the TME and poor prognosis for colorectal and gastric adenocarcinomas. Furthermore, an analysis on The Cancer Genome Atlas (TCGA) database also showed that the expression of STING is positively correlated with the infiltration of almost all immune cells, including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) [24]. For example, the chromosomal instability in tumor cells can lead to sustained activation of the cGAS-STING pathway, inducing chronic inflammation and immunosuppressive TME, desensitizing cells to inflammatory responses and aiding tumor cells in immune escape [24,25]. Mutagenic agents such as 7,12-dimethyl-benz(a)anthracene (DMBA), cisplatin, and etoposide promote skin carcinogenesis by triggering the STING-dependent production of inflammatory cytokines and the infiltration of phagocytic cells [26]. Similarly, chromosomally unstable tumor cells exploit the persistent activation of noncanonical NF-κB signaling following STING activation to boost their invasion and metastasis [27]. One hallmark of the immunosuppressive TME is the increased expression of immune checkpoint protein indoleamine 2,3-dioxygenase (IDO). STING activation can stimulate IDO activity in DCs within the TME, which in turn activates Tregs, suppresses the infiltration of CD8+ T cells into tumors, and dampens their antitumor activity [28].
As a crucial component of the innate immune system, the cGAS-STING pathway plays a significant regulatory role in the occurrence and development of tumors [29]. It is involved in the inhibition of tumor progression through promoting the cytotoxic effects of T cells and NK cells, inducing apoptosis and autophagy [30,31]. Meanwhile, it promotes tumor development through chronic inflammation induced by its sustained activation and inhibition on DNA damage repair [10]. This review will provide a concise summary on the recent advances in agonists and inhibitors of the cGAS-STING pathway. We hope it is of value to biomedical researchers working in the domain of drug design and clinical translation.

2. cGAS-STING Agonists

The cGAS-STING pathway bridges innate and adaptive immunity against tumors [32,33]. Both indirect and direct activations of the cGAS-STING pathway can stimulate antitumor immune responses. Indirect agonists do not bind directly to STING but instead induce a series of reactions that activate the cGAS-STING pathway. Indirect activation includes various cancer treatments, such as DNA-damaging chemotherapies using cisplatin [34], camptothecin [35], doxorubicin [36], paclitaxel [37], and etoposide [38,39]. Some activation is induced by impairing the DNA damage response using poly ADP-ribose polymerase (PARP) [40,41], ataxia telangiectasia and rad3-related (ATR) inhibitors [42], as well as radiation [43]. The activation within tumor cells is triggered by cellular dsDNA accessible to cGAS. Direct agonists bind directly to STING. Direct activation supports the formation of memory T cells and contributes to long-lasting immune responses against cancer [32].
Furthermore, cGAS-STING agonists stimulate the secretion of the chemokine CXCL10 in an IFN-I-dependent manner [44], which facilitates the recruitment of antigen-specific CD8+ T cells to infiltrate into the tumor and elicit an effective antitumor immune response [33]. Notably, when the STING protein is activated in tumor cells, it triggers the production of IFN-β, which reverses the downregulation of MHC-I expression, leading to the escape of tumor cells from immune recognition by cytotoxic T-lymphocytes (CTLs) [45]. The multifaceted effects of cGAS-STING agonists suggest that they are potential anticancer agents. The actions of diversified agonists are summarized in Figure 2.

2.1. Cyclic Dinucleotides

Cyclic dinucleotides (CDNs) consist of cyclic di-GMP (c-di-GMP), cyclic di-AMP (c-di-AMP), and cGAMP. After activation by DNA, cGAS catalyzes the synthesis of cGAMP, which then activates the STING-mediated IFN-I response [46]. cGAMP has canonical or noncanonical structures according to the orientation of phosphodiester bonds. Canonical CDNs with a 3′,3′ linkage orientation originate from bacteria; however, they have been largely disregarded as potential drug candidates for their inability to activate all human STING (hSTING) isoforms and translational limitations [47]. Noncanonical CDNs include synthetic forms like 2′,2′-cGAMP, which has two 2′,5′ phosphodiester bonds that do not exist naturally [48,49]; 3′,2′-cGAMP, which is identified in Drosophila melanogaster as a product of cGAS-like receptors to recognize dsRNA [50,51]; and 2′,3′-cGAMP, which is generated intracellularly by mammalian cGAS and shows affinity for hSTING variants. Their affinity for hSTING is in the order of 2′,3′-cGAMP > 2′,2′-cGAMP > 3′,3′-cGAMP ≈ 3′,2′-cGAMP [52,53]. The binding profiles of 2′,3′-cGAMP to the STING C-terminal domain and a detailed view of cGAMP within STING are shown in Figure 3 [53]. Natural CDNs are poor drug candidates due to their susceptibility to hydrolytic degradation by phosphodiesterases; but they could provide insights into the design of STING agonists.
Current research is exploring chemically modified CDNs and non-nucleotide small molecules as synthetic agonists for hSTING. The emphasis is on synthetic CDN analogs that are nonhydrolyzable and contain a combination of 2′,5′ and 3′,5′ phosphorothioate bonds, mimicking the structural characteristics of natural CDNs [54], such as 3′,3′-cGAMP and 3′,2′-cGAMP. The structures of some examples are shown in Figure 4. Compound 1 (ADU-S100) is the first CDN class STING agonist in clinical trials, which has exhibited high affinity for both mouse STING (mSTING) and hSTING, and significantly enhanced the production of IFN-I. The mixed phosphorothioate bonds improve the stability and lipophilicity. The substitution of nonbridging oxygen atoms at the phosphate bridge with sulfur atoms enhances resistance to phosphodiesterase degradation, potentially promoting cellular uptake and cytosolic delivery [55,56,57]. Despite its favorable features, the clinical trial of 1 for recurrent or metastatic squamous cell carcinoma was terminated due to limited antitumor efficacy [58]. Compound 2 (MK-1454) strongly activated STING in head and neck squamous cell carcinoma and has entered phase II clinical trials [59]. Compound 3 (E7766) demonstrated promising antitumor effects in mice, including the ability to induce tumor-specific immune memory. In order to improve the therapeutic efficacy, transannular macrocyclic bridges were used to stabilize the CDN in its bioactive U conformation [60]. Other agonists, such as 4 (TAK-676), have entered phase I clinical trials to investigate antitumor effects [61]. The synthesis of natural CDNs and their analogs is a precondition for the clinical application of CDN agonists. In this regard, several challenges need to be addressed. For instance, modified CDNs often exhibit poor metabolic stability, low cellular uptake, and limited utilization rates [62]; most clinical studies rely on intra-tumoral drug delivery, and the large-scale industrial synthesis of CDNs remains limited. These challenges may be overcome by the rational design and synthesis of novel CDN analogs, the development of efficient delivery systems, and the application of combination therapies.

2.2. Non-CDNs

Non-CDN-based agonists for STING have been developed as promising alternatives to CDNs. STING can be activated by multiple non-CDN agonists, such as synthetic small molecules, natural products, and so on. The structures and general information of some STING agonists are shown in Figure 5 and Table 1. Flavone acetic acid (FAA) 5 was initially utilized as a vascular-disrupting agent and exhibited therapeutic potential by inducing hemorrhagic necrosis in murine tumors [34,63]. The exploration of STING agonists for cancer treatment commenced with the investigation of 5, predating the discovery of the STING pathway; however, it was hindered by a narrow therapeutic window and poor pharmacokinetic properties [64]. To meet these challenges, a refined derivative 6 (DMXAA) was developed [65,66]. Originally an anti-angiogenic drug, 6 displayed a potent cytotoxic effect on tumor cells across various mouse models. Subsequently, it was found that both 5 and 6 can directly interact with STING, activating its signaling cascade and thus displaying anticancer potential [67]. However, 6 failed in phase III clinical trials for non-small cell lung cancer, which was attributed to its inability to activate hSTING except mSTING [68,69], and to induce downstream IFN-I signaling [70,71,72]. The differences between hSTING and mSTING are quite subtle, suggesting that further fine modifications on the structure of 6 may lead to effective hSTING agonists [34]. In fact, some derivatives of 6 were designed to target the hSTING [73]. Compound 7 (α-Mangostin) is a weak agonist of hSTING and a natural product isolated from mangosteen, possessing the same anthrone skeleton as 6 [73,74]. It showed higher efficiency in activating hSTING than in activating mSTING. These studies lay the foundation for the rational design of 6-like STING agonists. Species specificity remains a key challenge to be overcome. Therefore, the optimization of small molecules akin to 6 may be a feasible strategy for discovering novel inducers of human interferon to treat cancers.
Compound 8 (SR-717) was screened from 100,000 compounds and its membrane permeability was optimized for systemic and oral administration. Crystallographic analysis revealed that two 8 bind at the base of the STING dimer inter-subunit cleft, inducing a closed-lid conformation resembling the binding mode of 2′,3′-cGAMP. The paired 8 interact with the same contact residues as 2′,3′-cGAMP, allowing them to competitively bind to STING. Intraperitoneal administered 8 at doses (15 or 30 mg kg–1) increased cytokine levels and exhibited significant antitumor activity against B16-F10 melanoma and MC38 colorectal adenocarcinoma in mice. Moreover, it hindered lung nodule formation, showing a potential against metastasis. Compound 8 binds to both hSTING and mSTING variants and has entered preclinical studies for melanoma [75].
Benzothiophene oxobutanoic acid 9 (MSA-2) was identified to be a potential STING agonist by high-throughput screening of a library containing about 2.4 million compounds [76]. It exhibited high cellular permeability and STING selectivity, and induced dose-dependent phosphorylation of both TBK1 and IRF3. Interestingly, it formed a noncovalent dimer in solution and bound to the CDN-binding pocket of STING with high affinity (KD = 8 nM) and slow off-rate (t1/2 = 1.3). The dimerized 9 interact through the aromatic cores, pre-associating in solution before binding to STING at the same site as 2′,3′-cGAMP. This binding mode stabilizes a closed-lid conformation similar to that induced by 2′,3′-cGAMP-bound STING, effectively bridging across the STING homodimer and noncovalently cross-linking the two subunits. The selectivity of 9 for tumor tissue was shown by the higher concentrations of 9 in subcutaneous MC38 tumors than in plasma or organs, which increased production of IFN-β and proinflammatory cytokines at the tumor site. Consequently, treatment with 9 led to complete regression of tumors in 80–100% of mice bearing MC38 colon carcinoma when administered intratumorally, subcutaneously, or orally. Remarkably, orally administered 9 in mice showed comparable or superior efficacy to a cGAMP analogue delivered intratumorally or subcutaneously, demonstrating its great clinical potential. In terms of immune modulation, 9 demonstrated robust long-term antitumor immunity and enhanced the efficacy of immune checkpoint blocker (ICB) to PD-1 in MC38 and CT26 colorectal, LL-2 lung cancer and B16-F10 melanoma models. In brief, 9 enhanced the selectivity of STING agonists, thus overcoming the unexpected systemic inflammation and associated toxicity resulting from excessive activation of the cGAS-STING pathway in normal tissues.
In 2018, the first non-CDN-type STING agonist 10 (di-ABZI) was reported, which induced a potent antitumor activity to completely curb the tumor [77]. This agonist was derived from the modification of amidobenzimidazole, which has a certain affinity for the STING subunit and dimerization further enhanced the affinity. Similar to cGAMP, 10 selectively induced dose-dependent activation of STING and secretion of IFN-β, exhibiting over 400-times greater potency than cGAMP in human peripheral blood mononuclear cells. Analysis on the binding mechanism revealed that cGAMP induced a closed conformation of the STING, while 10 bound to STING in an open conformation. The success of 10 suggests that STING agonists could be developed on a new mechanism of action. The evaluation on the anticancer effects of 10 in a syngeneic colon tumor model demonstrates that it induced tumor eradication in 80% of the treated mice and significantly improved the survival rates.
Table 1. Status of cGAS-STING agonists in clinical trials.
Table 1. Status of cGAS-STING agonists in clinical trials.
CompoundSubject TumorsAdimistrationCombinationPhaseNCT NumberReference
1Recurrent or metastatic squamous cell carcinoma of the bronchusi.t.†AloneIINCT03937141[58]
2Head and neck squamous cell carcinomai.t.Alone and combined with pembrolizumabIINCT04220866[59]
Solid tumors and lymphomai.t.Alone and combined with pembrolizumabINCT03010176[58]
3Advanced solid tumor; lymphomai.t.AloneINCT04144140[60]
Urinary bladder neoplasmIntravesical injectionAloneINCT04109092
4Solid neoplasmi.v.Alone and combined with pembrolizumab following radiotherapyINCT04420884[61]
Carcinoma, non-small-cell lung, triple-negative breast neoplasm, squamous cell carcinoma of head and necki.v.Alone and combined with pembrolizumab following radiotherapyINCT04879849
5Various malignant solid tumorsi.v.Constant infusion with alkalinization//[78]
6Solid tumorsi.v.AloneINCT00863733[79]
Non-small cell lung cancern.s.Alone and combined with carboplatin and paclitaxelI/IINCT00832494
7Cervical cancer stem-like cellsi.g.Alone and combined with cisplatin//[80]
Colon cancer stem cellsi.p.Alone and combined with 5-FU[81]
8Melanomai.p./Preclinical studies/[75]
9Colorectal carcinomai.t., i.h.; p.o./Preclinical studies/[76]
10Colorectal carcinomai.p./Preclinical studies/[77]
† i.t., intratumoral injection; i.v., intravenous injection; n.s., not specified; i.g., oral gavage; i.p., intraperitoneal injection; i.h., subcutaneous injection; p.o., oral administration.

2.3. Metal-Based cGAS-STING Agonists

Some metallodrugs could participate in both innate and adaptive immunity as chemoimmunotherapeutic agents to reverse immune evasion [82]. Recent studies show that metal complexes are promising agonists of the cGAS-STING pathway. Platinum drugs are the first-line chemotherapeutic agents in clinics for most solid tumors. They work by damaging DNA in tumor cells, leading to the production of DNA fragments and activation of the cGAS-STING pathway. Combining cisplatin and STING agonists can synergistically activate the cGAS-STING pathway, implying a close relationship between Pt complexes and this pathway [83]. For example, PtII triphenylamine complexes 11 and 12 could damage mitochondrial/nuclear DNA and the nuclear envelope to activate the cGAS-STING pathway, inducing pyroptosis in cancer cells and an intense anticancer immune response in vitro and in vivo [84]. A novel PtIV complex 13 is composed of oxaliplatin and acetaminophen; it induced STING activation and mitochondrial membrane remodeling, leading to pyroptosis [85]. Additionally, two PtIV complexes 14 and 15 bearing MSA-2 demonstrated significant antitumor immune effects and stimulation on the STING pathway. This strategy suggests that combining DNA-damaging agents with STING agonists is a promising approach for cancer therapy [86].
Other metal complexes have also shown promising regulatory effects on the cGAS-STING pathway. For example, mitochondria-targeted gold(I) complex 18 was designed, which generated a substantial amount of reactive oxygen species (ROS) and facilitated DNA excretion. The ROS-induced immunogenic cell death (ICD) and the DNA-activated cGAS-STING pathway triggered a robust anticancer immune response in hepatocellular carcinoma. This approach may offer an innovative strategy for designing chemoimmunotherapeutics [87]. The impact of mitochondrial DNA (mtDNA) on cancer immunotherapy has come into view. A rhodium(III) complex 19 has been reported as an mtDNA intercalator, inducing the release of mtDNA fragments into the cytoplasm and activating the cGAS-STING pathway. This study provides valuable insights into the development of biomacromolecule-targeted immunotherapeutic agents [88]. The structures of some representative metal-based cGAS-STING agonists are shown in Figure 6.
In 2018, Jiang discovered that viral infections lead to a significant increase in the cytoplasmic concentration of Mn2+, and there was a close dependency between Mn2+ and the cGAS-STING pathway [89], which has aroused the interest in Mn2+ for immunotherapy. Mn2+ has three main effects on the cGAS-STING pathway: direct activating cGAS and inducing a noncanonical catalytic synthesis of 2′,3′-cGAMP [89,90]; enhancing the binding ability of STING to cGAMP, thereby strengthening the cGAS-STING pathway [89]; and activating cGAS in a non-dsDNA-dependent manner [91,92]. Currently, several tumor treatment strategies based on the activation of the cGAS-STING pathway by Mn2+ have been developed [92]. Mn2+ was demonstrated to activate the STING pathway in colon cancer cells, leading to production of IFN-I. It downregulated dihydroxyacid dehydratase expression in tumor cells, inducing lipid peroxidation and increasing ROS levels, ultimately triggering ferroptosis [93].
While Mn2+ monotherapy shows promise, combination therapies leveraging the immunomodulatory effect of Mn2+ and other drugs may bring more encouraging results. An anthracycline antitumor drug doxorubicin (DOX) was encapsulated in amorphous porous manganese phosphate (APMP) nanoparticles with a phospholipid (PL) outer layer, forming PL/APMP-DOX nanoparticles [94]. The PL layer protects the nanoparticles and targets tumor cells. In the acidic TME, these nanoparticles degraded, rapidly releasing Mn2+ and DOX to activate the cGAS-STING pathway. Moreover, biomineralized manganese oxide nanoparticles (Bio-MnO2 NPs) were reported to convert endogenous H2O2 to O2, enhancing the radiosensitivity of non-small cell lung cancer cells [95]. The release of Mn2+ from these nanoparticles activates the STING pathway, significantly inhibiting tumor growth in mice with lung cancer [96].
Recently, we synthesized MnII complexes 16 and 17 (MnPC and MnPVA), where 1,10-phenanthroline is a non-toxic DNA intercalator, and valproic acid is an inhibitor of histone deacetylases (HADCs). They not only caused DNA damage but also inhibited its repair, leading to the leakage of DNA fragments into the cytoplasm to activate the cGAS-STING pathway in tumor and immune cells. As a result, tumor infiltration by DCs and macrophages was enhanced, IFNs and pro-inflammatory cytokines were increased, and cytotoxic T cells were stimulated to kill cancer cells both in vitro and in vivo. Notably, 16 and 17 exhibited greater immunocompetence and antitumor activity than Mn2+ ions, demonstrating their potential as promising chemoimmunotherapeutic agents for cancer treatment [97]. They are the first multifunctional MnII complexes that suppress tumor cells, mainly through activating antitumor immunity via the DNA damage-initiated cGAS-STING pathway. Their anticancer mechanisms are show in Figure 7.
Although metal-based cGAS-STING agonists have demonstrated promising activities, the clinical application of these compounds is limited by their side effects [98]. For example, Pt drugs exhibit poor selectivity, affecting not only cancer cells but also healthy tissues, leading to severe side effects [99]. Additionally, hematologic toxicity, hepatotoxicity, cardiotoxicity, gastrointestinal toxicity, and hypersensitivity reactions involving immune reactions can pose serious problems [100,101,102]. The risk of secondary immune-related cancers following metal drug therapy still exists [98]. In short, a deep understanding of the mechanisms of metal complexes is needed for the design of more efficient and less toxic cGAS-STING agonists.

2.4. Other Agonists

β-Arrestin 2 plays an important role in numerous signaling cascades associated with various diseases, such as metabolic disorders and cancers, primarily through G protein-coupled receptor (GPCR) pathways [103]. Recent studies revealed that β-arrestin 2 interacts with cGAS, promoting the binding of dsDNA to cGAS and subsequently enhancing the production of cGAMP. This interaction leads to the deacetylation of β-arrestin 2 at Lys171, facilitating the activation of the cGAS-STING pathway and the production of IFN-β, ultimately contributing to immune evasion [104].
Chitosan is an appealing alternative of alum in vaccine adjuvants due to its composition of N-acetylated and deacetylated glucosamines [105]. It can trigger the release of intracellular DNA, activating cGAS and initiating the cGAS-STING pathway, and thereby promoting the production of IFN and IFN-stimulated genes (ISGs) [106]. Chitosan-based adjuvants are suitable for oral and intranasal vaccines and are gaining recognition for their cost-effectiveness, easy availability, high biocompatibility, and biodegradability. However, the limited water solubility restricts their application. Additionally, several protein agonists have been identified to activate cGAS [106]. For instance, GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) enhances DNA-binding affinity [106,107], tripartite motif-containing 21 (TRIM21) aids in cGAS detection in viral genomes [108], zinc-finger CCHC-type-containing protein 3 (ZCCHC3) enhances cGAS sensing of DNA and oligomerization [109], and poly(rC)-binding protein 1 (PCBP1) enhances cGAS sensing of DNA and oligomerization [110].
In brief, despite the structural and source diversity, indirect agonists of the cGAS-STING pathway mainly function through promoting intracellular ROS production, transcriptional regulation, and ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibition. These mechanisms provide enlightenment for the development of cGAS-STING pathway agonists.

3. cGAS-STING Inhibitors

As understanding on the cGAS-STING pathway deepens, it is realized that excessive activation of this pathway could prolong the expression and secretion of inflammatory cytokines like IFN, leading to autoimmune diseases, such as Aicardi–Goutieres syndrome and lupus [111,112]. The diseases are triggered mainly by two ways: one involves abnormal accumulation of DNA, leading to continuous activation of the cGAS-STING pathway and sustained release of inflammatory cytokines like IFN-I; the other involves mutations in STING itself, causing its continuous activation independent of upstream signals, thereby leading to autoimmune diseases [113]. Furthermore, neurological disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, and age-related diseases are closely associated with abnormal activation of this pathway [114]. These adverse effects constitute the alarm system of cGAS-STING activation. Modulating the cGAS–STING pathway may offer a new approach to treating acute or chronic inflammatory diseases shown in Figure 8. It was demonstrated that cGAS activation causes autoimmune diseases in Trex1-/- and DNaseII-/- mice, suggesting that inhibiting cGAS could prevent and treat some human autoimmune diseases triggered by self-DNA [115]; and tonic prime-boost of STING signaling mediates Niemann–Pick disease type C [116]. These examples rationalize the development of cGAS-STING inhibitors.

3.1. STING Inhibitors

STING inhibitors hold great potential for treating tumors and inflammatory diseases, warranting further investigation in clinical trials [117,118]. Based on the inhibition mode, they can be categorized into palmitoylation inhibitors, CDN pocket inhibitors, and TBK1 inhibitors. Some of these inhibitors and their structures are summarized in Figure 9 and Table 2.
The STING activity is affected by polyubiquitination and phosphorylation, sumoylation, nitro-alkylation, oxidation, carbonylation, and disulfide bond formation [117,119]. Blocking STING palmitoylation represents an effective strategy for inhibiting the STING activation. STING inhibitors disrupt palmitoylation by covalently binding to Cys88 or Cys91 residues in the transmembrane region of the STING protein [120]. Nitrofuran derivatives 20–23 effectively inhibited STING palmitoylation and strongly reduced the STING-mediated IFN-β reporter activity [120]. Similarly, 24 inhibited STING palmitoylation through irreversible Cys91-dependent modification with higher specificity for hSTING over mSTING, thus regulating systemic inflammation [120]. Additionally, endogenous nitro-fatty acid 25 mediates anti-inflammatory, antioxidant, and cytoprotective effects. Their derivatives also covalently modified the Cys88 and Cys91 residues of STING to inhibit its palmitoylation, thereby inhibiting the production of IFN-I in fibroblasts from patients with STING-associated vasculopathy in infancy [121]. Compound 26 and its analog 27 inhibited STING oligomerization and activation by covalently modifying Cys148 [122,123]. Compound 28 formed adducts with Cys91 of STING, as well as with cysteines of other immune-related proteins [124]. Furthermore, it inhibited cGAMP-mediated STING in peripheral blood mononuclear cells. The cyclin-dependent protein kinase (CDK) inhibitor 29 (palbociclib) directly binds to STING and inhibits its activation in both mouse and human cells. Mechanistically, 29 targets Y167 of STING to block its dimerization, binding with cyclic dinucleotides and trafficking [125].
CDN pocket inhibitors target the C-terminal ligand-binding domain of STING, competitively binding to STING endogenous ligands. Furthermore, they promote the degradation of STING protein and regulate the STING pathway negatively. The natural cyclic peptide 30 was derived from the purple periwinkle plant [120]. It binds specifically to the activation pocket of the STING C-terminal, preventing the recruitment of IRF3 and maintaining the integrity of the STING-TBK1 interaction, thereby inhibiting the activation of the downstream signaling pathway mediated by STING [120]. It exhibited low cytotoxic side effects in mouse models and was expected to be improved after further modifications [126]. Compound 31, as a specific STING inhibitor that binds to the CDN-binding pocket, is one of the promising lead compounds for the treatment of diseases related to aberrant STING activation [121]. It was discovered to compete with cGAMP for STING binding in the computer docking, with the affinity for the STING CDN-binding pocket being higher than cGAMP (IC50 = 76 nM). It locked STING into an open, inactive conformation, inhibiting its activation and thus the production of IFN-I and inflammatory cytokines in Trex1-/- mice.
Inhibiting TBK1 is a viable method for STING inhibition. TBK1 inhibitor 32 is an ideal probe for the analysis of biological properties of TBK1 in immune, neuroinflammatory, obese, or cancerous models [127,128]. It inhibited Toll-like receptor 3-induced IFN-III phosphorylation in Ramos cells and IFN-I secretion in human primary monocytes. In monocyte-derived macrophages, 32 responded to dsDNA and cGAMP, inhibiting the secretion of IFN-β [129].
Table 2. STING inhibitors subjected to preclinical trials.
Table 2. STING inhibitors subjected to preclinical trials.
FunctionCompoundSubjectModelActivityReference
STING palmitoylation inhibitors20, 21Human/MiceTrex1-/- miceImproves systemic inflammation[120]
22, 23MiceTrex1-/- miceImproves systemic inflammation[120]
24Human/MiceTrex1-/- miceImproves systemic inflammation[120]
25Human/MiceSAVI patients with fibroblast cellsInhibits the production of IFN-I[121]
26Human/MiceBMDMs cellInhibits the activation of STING in mouse and human cells and increases the survival rate of mice[123]
Peripheral blood monocyte
TrexlD18N/D18N mice of AGS
27Human/MiceMonocyteInhibits the covalent modification of STING and block the cGAS-STING signaling pathway[130]
BMDMs cell
28HumanPeripheral blood mononuclear cellsInhibits cGAMP-mediated STING[124]
29Human/MiceHEK293TLowers the incidence of autoimmune diseases[125]
Mouse peritoneal macrophages
THP1 cells
CDN pocket inhibitors30Human/MiceTrex1-/- BMDMs cellsInhibits the expression of IFN-I and pro-inflammatory cytokines and reduces self-inflammatory response[121]
Trex1-/- mice
31Human/MiceTrex1-/- miceImproves immune system[131]
TBK1 inhibitors32HumanRamos cellsInhibits Toll-like receptor 3-induced IFN-III phosphorylation[127]
Human primary monocytesInhibits IFN-I secretion
Monocyte-derived macrophages

3.2. cGAS inhibitors

Targeting cGAS is an important strategy for developing inhibitors of the cGAS-STING pathway. cGAS inhibitors include two categories—competitors for the ATP or GTP binding site of cGAS, and inhibitors of dsDNA binding to cGAS. Several such inhibitors are summarized in Figure 10 and Table 3.
A high-affinity inhibitor 33 was developed from a low-affinity fragment by Pfizer researchers. The biochemical and structural data suggest that it binds to the cGAS active site. Although its inhibitory effect at the cellular level was modest, it validated the druggability of cGAS inhibitors, provided a high-affinity tool compound, and established a high-throughput assay for identifying next-generation cGAS inhibitors [132]. Furthermore, 34 and 35 were identified as selective inhibitors of the DNA pathway in human cells, with no impact on the RIG-I-MAVS or Toll-like receptor pathways. These compounds introduced a novel class of hcGAS inhibitors that are active in cells, presenting a new chemical framework for creating probes to investigate cGAS function and develop treatments for autoimmune diseases [133]. Other hcGAS inhibitors such as 36 and 37 are optimized derivatives of the mcGAS inhibitor 38. They occupy the catalytic site of cGAS, reducing its affinity for ATP and GTP and inhibiting its activity. The specificity and potency of these drug candidates were further demonstrated in human myeloid cells, including primary macrophages [134,135]. Further structural optimizations on both the side chain and central tricyclic core of 36 resulted in several subseries. Compound 39 is the most potent one with cellular IC50 values of 1.38 and 11.4 μM for h- and mcGAS, respectively. Mechanistic studies confirmed its direct targeting to cGAS. Furthermore, 39 exhibited superior in vivo anti-inflammatory effects in a lipopolysaccharide-induced mouse model [136]. Compounds 40 (perillaldehyde) exhibited strong inhibitory effects on both mcGAS and hcGAS and demonstrated excellent anti-inflammatory properties [137]. It inhibited cGAS activity, thereby suppressing innate immune responses triggered by cytosolic DNA. Consequently, the 40-treated mice were more susceptible to herpes simplex virus type 1 (HSV-1) infection. Since 40 is derived from Perilla frutescens, the results suggest that natural compounds could be potential inhibitors of cGAS [136,137]. This speculation is further supported by natural compound 41 (epigallocatechin gallate, EGCG), which disrupted existing G3BP1-cGAS complexes and inhibited DNA-triggered cGAS activation [138,139]. Interestingly, 42 (Aspirin) was found to directly acetylate cGAS and efficiently inhibit cGAS-mediated immune responses [140]. Moreover, it effectively suppressed self-DNA-induced autoimmunity in Aicardi–Goutières syndrome (AGS) patient cells and in an AGS mouse model.
Disrupting the binding between cGAS and dsDNA is an approach to inhibit the activation of cGAS. Compound 43 (Suramin) was discovered to inhibit the STING pathway by displacing bound DNA from cGAS and inhibiting cGAS enzymatic activity. Compound 43 or its analogs could be utilized as anti-inflammatory drugs [141]. Compounds 44 (Acrinamin) and 45 (Oxychloroquine) specifically bind to the grooves of dsDNA at the interface of cGAS/dsDNA interaction, inhibiting the interaction between cGAS and dsDNA and thus suppressing cGAS activation [142]. These compounds may serve as potential therapeutics for diseases such as AGS or systemic lupus erythematosus (SLE).
Table 3. cGAS inhibitors in preclinical trials.
Table 3. cGAS inhibitors in preclinical trials.
FunctionCompoundSubjectModelActivityReference
Inhibits cGAS33Human cGAS//[132]
34, 35Human cGASTHP-1 cellsInhibits DNA pathway[133]
36, 37Human cGASTHP-1 cellsInhibits cGAS activity induced by dsDNA[135]
RAW 264.7 cells
38Mice cGASAGS miceInhibits IFN-I expression[134]
39Human/Mice cGASTHP-1 cells Inhibits inflammation [136]
40Human/Mice cGASAGS miceImproves self-induced inflammation response of DNA[137]
41Mice cGASAGS miceSuppresses DNA-triggered cGAS activation by preventing the formation of G3BP1-cGAS complex, reducing auto-inflammatory response[139]
42Human/Mice cGASAGS patient cells and AGS miceInhibits cGAS-mediated immune responses and self-DNA-induced autoimmunity[140]
Inhibits interaction with dsDNA/cGAS43Human cGASTHP-1 cellsInhibits cGAS-mediated IFN-I response[141]
44, 45Human/Mice cGASTrexl-/- miceActs on AGS/SLE mice[142]

4. Perspectives

The cGAS-STING pathway plays an important role in the pathogenesis and progression of cancers and autoimmune diseases. In most cases, activating this pathway leads to antitumor immune responses and cancer inhibition. Therefore, cGAS-STING agonists could be used alone or in combination with other drugs to treat various cancers. However, as a key inducer of IFN-I responses, cGAS-STING also promotes stage-specific tumor initiation and proliferation, and mediates the pathogenesis of autoimmune diseases. Thus, the side effects of STING agonists should be considered in cancer therapy. In this review, we have shown various approaches to produce modulators of the cGAS-STING pathway, nevertheless, several challenges remain to be addressed in the future.
Firstly, STING agonists face clinical challenges in tumor treatment because they show poor efficacy in cancer patients. For instance, ADU-S100 monotherapy demonstrated only a 2.1% overall response compared to untreated groups [143]. Similarly, MK-1454 showed no overall response for monotherapy when administered intratumorally, and a 24% overall response when combined with the anti-PD-1 monoclonal antibody pembrolizumab [144]. Neither of them consistently demonstrated abscopal effects with non-injected distal tumors shrinking. These results lowered the initial expectations on STING agonists usage as potential anticancer treatments. The results may also suggest that standard cancer therapy is insufficient, and combined therapies with chemotherapy, radiotherapy, or targeted therapy may produce more beneficial effects. The disparity between the preclinical efficacy and the initial clinical results further underscores the need to comprehensively study the biological and pharmacological mechanisms of STING agonists. A deep understanding of the mechanism can promote the development of new agents or drug combinations and allow us to fine-tune the inflammatory TME to fully exploit the potential of the cGAS-STING pathway in immunotherapy.
Secondly, CDNs like ADU-S100 are quickly cleared from injection sites (t1/2 = 10–20 min) due to their poor pharmacokinetics resulting from metabolic instability and membrane impermeability [145]. This limitation may be addressed by increasing the frequency of administration, but this poses challenges, especially for image-guided tumor injections. The transient drug exposure and localized STING activation at the tumor site may not be sufficient for generating the systemic T cell responses required for abscopal effects in in situ vaccination. Additionally, most STING agonists do not comply with the Lipinski’s rule—an empirical rule for evaluating the possibility of a compound to become a drug, leading to unsatisfactory clinical outcomes. They are also prone to degradation by phosphodiesterases and have limited modification possibilities due to large molecular weight. Therefore, it is necessary to design new compounds or drug delivery systems with improved pharmacokinetics. The aim is to improve cellular uptake, enhance cytosolic delivery, reprogram tumor-draining lymph nodes, and increase local retention of CDNs, which are highly important for intra-tumoral drug administration.
Thirdly, systemically administered STING agonists can induce a transient systemic inflammatory response resembling a cytokine storm, resulting in unexpected immune reactions and flu-like symptoms in patients. Particularly, T cells express high levels of STING and are vulnerable to STING-induced apoptosis [146,147]. Non-nucleotide small molecule STING agonists are potentially toxic to T cells [146]; they enter the cytosol directly through passive diffusion across cellular membranes, leading to uncontrolled STING activation in T cells and compromising antitumor adaptive immunity. A wide range of promising chemical, biomolecular, and pharmaceutical engineering approaches may solve this problem, with some being in development [148]. For instance, the non-nucleotide STING agonist MSA-2 utilizes a protonizable carboxylic acid group to enhance cellular membrane permeability in the acidic TME. Environmentally responsive drug carriers and conditionally cleavable chemical linkers have been developed, mainly for chemotherapeutics, to improve drug accumulation at tumor sites [149]. However, strategies to leverage TME for activating STING at tumor sites have not been extensively explored, which may enhance the effectiveness and safety of systemically administered STING agonists. The use of molecular targeting strategies, such as antibodies, peptides, and glycans, for STING agonists shows promise for achieving more tumor-selective activation of innate immunity and reducing inflammatory side effects.
Lastly, the use of cGAS-STING modulators may lead to excessive immune system activation and a cytokine storm, because cGAS and STING proteins are widely expressed across various tissues. In addition, systemic administration of STING agonists through intravenous or abdominal injection can overly activate the STING pathway, causing unnecessary inflammation in normal tissues. Therefore, cGAS-STING pathway modulators with tissue-targeting properties are required in the future to minimize the adverse reactions caused by the systemic immune effects. Novel drug delivery strategies such as antibody drug conjugates (ADCs) and drug release systems may help to avoid the adverse reactions of STING agonists.

5. Conclusions

The cGAS-STING pathway has emerged as a promising target in immuno-oncology. Academic researchers and pharmaceutical companies are actively developing agonists or inhibitors of the cGAS-STING pathway, aiming to translate them into applicable drugs. The importance of the cGAS-STING pathway for inflammation and immunity, coupled with checkpoint inhibitors, cytokine therapeutics, and cell-based therapies, underscore the compelling rationale for targeting this pathway in cancer immunotherapy. Preclinical studies of various STING agonists have shown encouraging results in tumor models, often leading to complete and long-lasting therapeutic responses in a majority of treated mice, even in models of highly immunosuppressive tumors [150]. Inhibitors of the cGAS-STING pathway are also potential drugs against autoimmune diseases and cancers. We believe that modulating the cGAS-STING pathway will become an effective strategy for the development of drugs to treat cancer and other autoimmune or inflammatory diseases in the future.

Author Contributions

Conceptualization, X.W. and X.Y.; investigation, L.C. and C.L.; original draft, X.Y. and J.Y.; review and editing, X.W. and X.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Nation Natural Science Foundation of China (82204443, 82304522, 22377053), Natural Science Foundation of Jiangsu Province (BK20210693), General Project of Basic Science in Colleges and Universities of Jiangsu Province (21KJB310013), Jiangsu Provincial Health Commission (Z2021064), Nanjing University of Chinese Medicine National Natural Science Foundation of China Counterpart Funding (No. XPT82204443), the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine), Phoenix Introduction Plan Talent Startover Project of Tangdu Hospital (NO. 2022YFJH002).

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

ABZIAmidobenzimidazole
ADCsAntibody-conjugated drugs
AGSAicardi–Goutières syndrome
APAPAcetaminophen
APCsAntigen-presenting cells
APMPAmorphous porous manganese phosphate
CAFsCancer-associated fibroblasts
c-di-AMPCyclic di-AMP
c-di-GMPCyclic di-GMP
CDKCyclin-dependent protein kinase
cGAMPCyclic GMP-AMP
CTLsCytotoxic T-lymphocytes
Cys88/Cys91Cysteine residue 88/91
DCsDendritic cells
DMBA7,12-Dimethyl-benz(a)anthracene
DMXAA5,6-Dimethylx-antheonone-4-acetic acid
DOXDoxorubicin
dsDNADouble-stranded DNA
EGCGEpigallocatechin gallate
ENPP1Ectonucleotide pyrophosphatase phosphodiesterase 1
EREndoplasmic reticulum
FAAFlavone acetic acid
FIHFirst-in-human
G3BP1GTPase-activating protein SH3 domain–binding protein 1
GIGastrointestinal
GPCRG protein-coupled receptor
GSHGlutathione
hSTINGHuman STING
HSV-1Herpes simplex virus type 1
ICBImmune checkpoint blockade
IDOIndoleamine 2,3-dioxygenase
IFN-IType I interferon
IKKIκB kinase
IL-6Interleukin-6
IRF3Interferon regulatory factor 3
ISGsInterferon-stimulated genes
MDSMyelodysplastic syndromes
MDSCsMyeloid-derived suppressor cells
MHC-IMajor histocompatibility complex class I
mSTINGMouse STING
NAFLDNon-alcoholic fatty liver disease
NF-κBNuclear factor kappa B
NKNatural killer
NPNanoparticle
OxaOxaliplatin
PAHPerillaldehyde
PAMPsPathogen-associated molecular patterns
PCBP1Poly-binding protein 1
PembroPembrolizumab
PhilaCancer prev res
PLPhospholipid
ROSReactive oxygen species
SAVISTING-associated vasculopathy with onset in infancy
SLEsystemic lupus erythematosus
TBK1TANK-binding kinase 1
TCGAThe Cancer Genome Atlas
TMETumor microenvironment
TregsRegulatory T cells
TRIM21Tripartite motif-containing 21
ZCCHC3Zinc-finger CCHC-type containing protein 3
ZFZinc-finger

References

  1. Jenson, J.M.; Chen, Z.J. cGAS goes viral: A conserved immune defense system from bacteria to humans. Mol. Cell 2024, 84, 120–130. [Google Scholar] [CrossRef] [PubMed]
  2. Liu, S.; Cai, X.; Wu, J.; Cong, Q.; Chen, X.; Li, T.; Du, F.; Ren, J.; Wu, Y.T.; Grishin, N.V.; et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 2015, 347, aaa2630. [Google Scholar] [CrossRef] [PubMed]
  3. Dvorkin, S.; Cambier, S.; Volkman, H.E.; Stetson, D.B. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity 2024, 57, 718–730. [Google Scholar] [CrossRef]
  4. Lu, Y.; Zhao, M.; Chen, L.; Wang, Y.; Liu, T.; Liu, H. cGAS: Action in the nucleus. Front. Immunol. 2024, 15, 1380517. [Google Scholar] [CrossRef]
  5. Hopfner, K.P.; Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 2020, 21, 501–521. [Google Scholar] [CrossRef] [PubMed]
  6. Decout, A.; Katz, J.D.; Venkatraman, S.; Ablasser, A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021, 21, 548–569. [Google Scholar] [CrossRef] [PubMed]
  7. Cao, L.L.; Kagan, J.C. Targeting innate immune pathways for cancer immunotherapy. Immunity 2023, 56, 2206–2217. [Google Scholar] [CrossRef] [PubMed]
  8. Fang, R.; Wang, C.; Jiang, Q.; Lv, M.; Gao, P.; Yu, X.; Mu, P.; Zhang, R.; Bi, S.; Feng, J.M.; et al. NEMO-IKKbeta Are essential for IRF3 and NF-kappaB activation in the cGAS-STING pathway. J. Immunol. 2017, 199, 3222–3233. [Google Scholar] [CrossRef] [PubMed]
  9. Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022, 12, 31–46. [Google Scholar] [CrossRef]
  10. Woo, S.R.; Fuertes, M.B.; Corrales, L.; Spranger, S.; Furdyna, M.J.; Leung, M.Y.; Duggan, R.; Wang, Y.; Barber, G.N.; Fitzgerald, K.A.; et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41, 830–842. [Google Scholar] [CrossRef]
  11. Corrales, L.; Glickman, L.H.; McWhirter, S.M.; Kanne, D.B.; Sivick, K.E.; Katibah, G.E.; Woo, S.R.; Lemmens, E.; Banda, T.; Leong, J.J.; et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015, 11, 1018–1030. [Google Scholar] [CrossRef] [PubMed]
  12. Guo, J.; Huang, L. Nanodelivery of cGAS-STING activators for tumor immunotherapy. Trends Pharmacol. Sci. 2022, 43, 957–972. [Google Scholar] [CrossRef] [PubMed]
  13. Lorenzi, S.; Mattei, F.; Sistigu, A.; Bracci, L.; Spadaro, F.; Sanchez, M.; Spada, M.; Belardelli, F.; Gabriele, L.; Schiavoni, G. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J. Immunol. 2011, 186, 5142–5150. [Google Scholar] [CrossRef] [PubMed]
  14. Li, X.; Khorsandi, S.; Wang, Y.; Santelli, J.; Huntoon, K.; Nguyen, N.; Yang, M.; Lee, D.; Lu, Y.; Gao, R.; et al. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nat. Nanotechnol. 2022, 17, 891–899. [Google Scholar] [CrossRef] [PubMed]
  15. Zheng, J.; Mo, J.; Zhu, T.; Zhuo, W.; Yi, Y.; Hu, S.; Yin, J.; Zhang, W.; Zhou, H.; Liu, Z. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol. Cancer 2020, 19, 133. [Google Scholar] [CrossRef] [PubMed]
  16. Kato, K.; Omura, H.; Ishitani, R.; Nureki, O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu. Rev. Biochem. 2017, 86, 541–566. [Google Scholar] [CrossRef] [PubMed]
  17. Nicolai, C.J.; Wolf, N.; Chang, I.C. NK cells mediate clearance of CD8+T cell–resistanttumors in response to STING agonists. Sci. Immunol. 2020, 5, 5. [Google Scholar] [CrossRef]
  18. Marcus, A.; Mao, A.J.; Lensink-Vasan, M.; Wang, L.; Vance, R.E.; Raulet, D.H. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor Cells to activate the NK cell response. Immunity 2018, 49, 754–763.e754. [Google Scholar] [CrossRef]
  19. Lam, A.R.; Bert, N.L.; Ho, S.S.; Shen, Y.J.; Tang, L.F.; Xiong, G.M.; Croxford, J.L.; Koo, C.X.; Ishii, K.J.; Akira, S.; et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res. 2014, 74, 2193–2203. [Google Scholar] [CrossRef]
  20. Motwani, M.; Pesiridis, S.; Fitzgerald, K.A. DNA sensing by the cGAS-STING pathway in health and disease. Nat. Rev. Genet. 2019, 20, 657–674. [Google Scholar] [CrossRef]
  21. Fu, J.; Kanne, D.B.; Leong, M.; Glickman, L.H.; McWhirter, S.M.; Lemmens, E.; Mechette, K.; Leong, J.J.; Lauer, P.; Liu, W.; et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 2015, 7, 283ra252. [Google Scholar] [CrossRef]
  22. Wang, H.; Hu, S.Q.; Chen, X.; Shi, H.P.; Chen, C.; Sun, L.J.; Chen, Z.J.J. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl. Acad. Sci. USA 2017, 114, 1637–1642. [Google Scholar] [CrossRef]
  23. Vasiyani, H.; Wadhwa, B.; Singh, R. Regulation of cGAS-STING signalling in cancer: Approach for combination therapy. Biochim. Biophys. Acta. Rev. Cancer 2023, 1878, 188896. [Google Scholar] [CrossRef]
  24. An, X.; Zhu, Y.; Zheng, T.; Wang, G.; Zhang, M.; Li, J.; Ji, H.; Li, S.; Yang, S.; Xu, D.; et al. An analysis of the expression and association with immune cell lnfiltration of the cGAS/STING pathway in pan-cancer. Mol. Ther. Nucleic Acids 2019, 14, 80–89. [Google Scholar] [CrossRef] [PubMed]
  25. Li, J.; Hubisz, M.J.; Earlie, E.M.; Duran, M.A.; Hong, C.; Varela, A.A.; Lettera, E.; Deyell, M.; Tavora, B.; Havel, J.J.; et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 2023, 620, 1080–1088. [Google Scholar] [CrossRef] [PubMed]
  26. Ahn, J.; Xia, T.L.; Konno, H.; Konno, K.; Ruiz, P.; Barber, G.N. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 2014, 5, 5166. [Google Scholar] [CrossRef] [PubMed]
  27. Bakhoum, S.F.; Ngo, B.; Laughney, A.M.; Cavallo, J.A.; Murphy, C.J.; Ly, P.; Shah, P.; Sriram, R.K.; Watkins, T.B.K.; Taunk, N.K.; et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 2018, 553, 467–472. [Google Scholar] [CrossRef]
  28. Munn, D.H.; Mellor, A.L. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance. Trends Immunol. 2016, 37, 193–207. [Google Scholar] [CrossRef] [PubMed]
  29. Chen, Q.; Sun, L.; Chen, Z.J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 2016, 17, 1142–1149. [Google Scholar] [CrossRef]
  30. Li, X.D.; Wu, J.; Gao, D.; Wang, H.; Sun, L.; Chen, Z.J. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 2013, 341, 1390–1394. [Google Scholar] [CrossRef]
  31. Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009, 136, 823–837. [Google Scholar] [CrossRef] [PubMed]
  32. Wang, J.; Li, P.; Yu, Y.; Fu, Y.; Jiang, H.; Lu, M.; Sun, Z.; Jiang, S.; Lu, L.; Wu, M.X. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 2020, 367, eaau0810. [Google Scholar] [CrossRef] [PubMed]
  33. Liu, Y.; Qin, Y.; Yang, B.; Zheng, H.; Qiao, S.; Luo, Z.; Li, R. Pseudorabies virus usurps non-muscle myosin heavy chain IIA to dampen viral DNA recognition by cGAS for antagonism of host antiviral innate immunity. J. Virol. 2024, 98, e0048324. [Google Scholar] [CrossRef]
  34. Che, X.; Du, X.X.; Cai, X.; Zhang, J.; Xie, W.J.; Long, Z.; Ye, Z.Y.; Zhang, H.; Yang, L.; Su, X.D.; et al. Single mutations reshape the structural correlation network of the DMXAA-human STING complex. J. Phys. Chem. B 2017, 121, 2073–2082. [Google Scholar] [CrossRef] [PubMed]
  35. Pepin, G.; Nejad, C.; Ferrand, J.; Thomas, B.J.; Stunden, H.J.; Sanij, E.; Foo, C.H.; Stewart, C.R.; Cain, J.E.; Bardin, P.G.; et al. Topoisomerase 1 inhibition promotes cyclic GMP-AMP synthase-dependent antiviral responses. mBio 2017, 8, e01611-17. [Google Scholar] [CrossRef] [PubMed]
  36. Luthra, P.; Aguirre, S.; Yen, B.C.; Pietzsch, C.A.; Sanchez-Aparicio, M.T.; Tigabu, B.; Morlock, L.K.; Garcia-Sastre, A.; Leung, D.W.; Williams, N.S.; et al. Topoisomerase II inhibitors induce DNA damage-dependent interferon responses circumventing ebola virus immune evasion. mBio 2017, 8, e00368-17. [Google Scholar] [CrossRef] [PubMed]
  37. Renoult, O.; Laurent-Blond, M.; Awada, H.; Oliver, L.; Joalland, N.; Croyal, M.; Paris, F.; Gratas, C.; Pecqueur, C. Metabolic profiling of glioblastoma stem cells reveals pyruvate carboxylase as a critical survival factor and potential therapeutic target. Neuro Oncol. 2024. [Google Scholar] [CrossRef] [PubMed]
  38. Maekawa, H.; Inoue, T.; Ouchi, H.; Jao, T.M.; Inoue, R.; Nishi, H.; Fujii, R.; Ishidate, F.; Tanaka, T.; Tanaka, Y.; et al. Mitochondrial damage causes inflammation via cGAS-STING signaling in acute kidney injury. Cell Rep. 2019, 29, 1261–1273. [Google Scholar] [CrossRef] [PubMed]
  39. Unterholzner, L.; Dunphy, G. cGAS-independent STING activation in response to DNA damage. Mol. Cell. Oncol. 2019, 6, 1558682. [Google Scholar] [CrossRef]
  40. Chabanon, R.M.; Muirhead, G.; Krastev, D.B.; Adam, J.; Morel, D.; Garrido, M.; Lamb, A.; Henon, C.; Dorvault, N.; Rouanne, M.; et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J. Clin. Investig. 2019, 129, 1211–1228. [Google Scholar] [CrossRef]
  41. Pantelidou, C.; Sonzogni, O.; De Oliveria Taveira, M.; Mehta, A.K.; Kothari, A.; Wang, D.; Visal, T.; Li, M.K.; Pinto, J.; Castrillon, J.A.; et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019, 9, 722–737. [Google Scholar] [CrossRef] [PubMed]
  42. Dillon, M.T.; Bergerhoff, K.F.; Pedersen, M.; Whittock, H.; Crespo-Rodriguez, E.; Patin, E.C.; Pearson, A.; Smith, H.G.; Paget, J.T.E.; Patel, R.R.; et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin. Cancer Res. 2019, 25, 3392–3403. [Google Scholar] [CrossRef] [PubMed]
  43. Wang, Z.; Chen, J.; Hu, J.; Zhang, H.; Xu, F.; He, W.; Wang, X.; Li, M.; Lu, W.; Zeng, G.; et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J. Clin. Investig. 2019, 129, 4850–4862. [Google Scholar] [CrossRef] [PubMed]
  44. Curtsinger, J.M.; Valenzuela, J.O.; Agarwal, P.; Lins, D.; Mescher, M.F. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 2005, 174, 4465–4469. [Google Scholar] [CrossRef] [PubMed]
  45. Yi, Y.; Qin, G.; Yang, H.; Jia, H.; Zeng, Q.; Zheng, D.; Ye, S.; Zhang, Z.; Liu, T.M.; Luo, K.Q.; et al. Mesenchymal stromal cells increase the natural killer resistance of circulating tumor cells via intercellular signaling of cGAS-STING-IFNbeta-HLA. Adv. Sci. 2024, 11, e2400888. [Google Scholar] [CrossRef] [PubMed]
  46. Sun, L.J.; Wu, J.X.; Du, F.H.; Chen, X.; Chen, Z.J.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339, 786–791. [Google Scholar] [CrossRef]
  47. Ablasser, A.; Goldeck, M.; Cavlar, T.; Deimling, T.; Witte, G.; Rohl, I.; Hopfner, K.P.; Ludwig, J.; Hornung, V. cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING. Nature 2013, 498, 380–384. [Google Scholar] [CrossRef]
  48. Ergun, S.L.; Fernandez, D.; Weiss, T.M.; Li, L. STING polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell 2019, 178, 290–301. [Google Scholar] [CrossRef]
  49. Zhou, C.; Chen, X.; Planells-Cases, R.; Chu, J.; Wang, L.; Cao, L.; Li, Z.; Lopez-Cayuqueo, K.I.; Xie, Y.; Ye, S.; et al. Transfer of cGAMP into bystander cells via LRRC8 volume-regulated anion channels augments STING-mediated interferon responses and anti-viral immunity. Immunity 2020, 52, 767–781.e766. [Google Scholar] [CrossRef]
  50. Slavik, K.M.; Morehouse, B.R.; Ragucci, A.E.; Zhou, W.; Ai, X.; Chen, Y.; Li, L.; Wei, Z.; Bahre, H.; Konig, M.; et al. cGAS-like receptors sense RNA and control 3’2’-cGAMP signalling in Drosophila. Nature 2021, 597, 109–113. [Google Scholar] [CrossRef]
  51. Holleufer, A.; Winther, K.G.; Gad, H.H.; Ai, X.; Chen, Y.; Li, L.; Wei, Z.; Deng, H.; Liu, J.; Frederiksen, N.A.; et al. Two cGAS-like receptors induce antiviral immunity in Drosophila. Nature 2021, 597, 114–118. [Google Scholar] [CrossRef] [PubMed]
  52. Shi, H.; Wu, J.; Chen, Z.J.; Chen, C. Molecular basis for the specific recognition of the metazoan cyclic GMP-AMP by the innate immune adaptor protein STING. Proc. Natl. Acad. Sci. USA 2015, 112, 8947–8952. [Google Scholar] [CrossRef] [PubMed]
  53. Zhang, X.; Shi, H.P.; Wu, J.X.; Zhang, X.W.; Sun, L.J.; Chen, C.; Chen, Z.J.J. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 2013, 51, 226–235. [Google Scholar] [CrossRef] [PubMed]
  54. Kwon, J.; Bakhoum, S.F. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020, 10, 26–39. [Google Scholar] [CrossRef] [PubMed]
  55. Yan, H.; Wang, X.; KuoLee, R.; Chen, W. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. Bioorg. Med. Chem. Lett. 2008, 18, 5631–5634. [Google Scholar] [CrossRef] [PubMed]
  56. Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014, 24, 374–387. [Google Scholar] [CrossRef] [PubMed]
  57. Li, L.; Yin, Q.; Kuss, P.; Maliga, Z.; Millan, J.L.; Wu, H.; Mitchison, T.J. Corrigendum: Hydrolysis of 2’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 2015, 11, 235. [Google Scholar] [CrossRef] [PubMed]
  58. Gogoi, H.; Mansouri, S.; Jin, L. The age of cyclic dinucleotide vaccine adjuvants. Vaccines 2020, 8, 453. [Google Scholar] [CrossRef]
  59. Chang, W.; Altman, M.D.; Lesburg, C.A.; Perera, S.A.; Piesvaux, J.A.; Schroeder, G.K.; Wyss, D.F.; Cemerski, S.; Chen, Y.; DiNunzio, E.; et al. Discovery of MK-1454: A potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J. Med. Chem. 2022, 65, 5675–5689. [Google Scholar] [CrossRef]
  60. Kim, D.S.; Endo, A.; Fang, F.G.; Huang, K.C.; Bao, X.; Choi, H.W.; Majumder, U.; Shen, Y.Y.; Mathieu, S.; Zhu, X.; et al. E7766, a macrocycle-bridged stimulator of interferon genes (STING) agonist with potent pan-genotypic activity. ChemMedChem 2021, 16, 1740–1743. [Google Scholar] [CrossRef]
  61. Carideo Cunniff, E.; Sato, Y.; Mai, D.; Appleman, V.A.; Iwasaki, S.; Kolev, V.; Matsuda, A.; Shi, J.; Mochizuki, M.; Yoshikawa, M.; et al. TAK-676: A novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies. Cancer Res. Commun. 2022, 2, 489–502. [Google Scholar] [CrossRef] [PubMed]
  62. Fang, R.; Jiang, Q.; Yu, X.; Zhao, Z.; Jiang, Z. Recent advances in the activation and regulation of the cGAS-STING pathway. Adv. Immunol. 2022, 156, 55–102. [Google Scholar] [CrossRef]
  63. Kerr, D.J.; Kaye, S.B. Flavone acetic acid--preclinical and clinical activity. Eur. J. Cancer Clin. Oncol. 1989, 25, 1271–1272. [Google Scholar] [CrossRef]
  64. Baguley, B.C.; Ching, L.M. DMXAA: An antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 1503–1511. [Google Scholar] [CrossRef]
  65. Woon, S.T.; Reddy, C.B.; Drummond, C.J.; Schooltink, M.A.; Baguley, B.C.; Kieda, C.; Ching, L.M. A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Oncol. Res. 2005, 15, 351–364. [Google Scholar] [CrossRef] [PubMed]
  66. Philpott, M.; Baguley, B.C.; Ching, L.M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 1995, 36, 143–148. [Google Scholar] [CrossRef]
  67. Xiao, Z.; Cui, X.; Liu, F.; Wang, Y.; Liu, X.; Zhou, W.; Zhang, Y. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation. Biochim. Biophys. Acta Mol. Basis Dis. 2024, 1870, 167149. [Google Scholar] [CrossRef]
  68. Temizoz, B.; Shibahara, T.; Hioki, K.; Hayashi, T.; Kobiyama, K.; Lee, M.S.J.; Surucu, N.; Sag, E.; Kumanogoh, A.; Yamamoto, M.; et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation. Front. Immunol. 2024, 15, 1353336. [Google Scholar] [CrossRef]
  69. Conlon, J.; Burdette, D.L.; Sharma, S.; Bhat, N.; Thompson, M.; Jiang, Z.; Rathinam, V.A.; Monks, B.; Jin, T.; Xiao, T.S.; et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 2013, 190, 5216–5225. [Google Scholar] [CrossRef] [PubMed]
  70. Graham, P.T.; Nowak, A.K.; Cornwall, S.M.J.; Larma, I.; Nelson, D.J. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. Front. Immunol. 2022, 13, 969678. [Google Scholar] [CrossRef]
  71. Prantner, D.; Perkins, D.J.; Lai, W.; Williams, M.S.; Sharma, S.; Fitzgerald, K.A.; Vogel, S.N. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J. Biol. Chem. 2012, 287, 39776–39788. [Google Scholar] [CrossRef] [PubMed]
  72. Lara, P.N., Jr.; Douillard, J.Y.; Nakagawa, K.; von Pawel, J.; McKeage, M.J.; Albert, I.; Losonczy, G.; Reck, M.; Heo, D.S.; Fan, X.; et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29, 2965–2971. [Google Scholar] [CrossRef] [PubMed]
  73. Gao, P.; Zillinger, T.; Wang, W.; Ascano, M.; Dai, P.; Hartmann, G.; Tuschl, T.; Deng, L.; Barchet, W.; Patel, D.J. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep. 2014, 8, 1668–1676. [Google Scholar] [CrossRef] [PubMed]
  74. Zhang, Y.; Sun, Z.; Pei, J.; Luo, Q.; Zeng, X.; Li, Q.; Yang, Z.; Quan, J. Identification of alpha-Mangostin as an Agonist of Human STING. ChemMedChem 2018, 13, 2057–2064. [Google Scholar] [CrossRef]
  75. Chin, E.N.; Yu, C.; Vartabedian, V.F.; Jia, Y.; Kumar, M.; Gamo, A.M.; Vernier, W.; Ali, S.H.; Kissai, M.; Lazar, D.C.; et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 2020, 369, 993–999. [Google Scholar] [CrossRef] [PubMed]
  76. Pan, B.S.; Perera, S.A.; Piesvaux, J.A.; Presland, J.P.; Schroeder, G.K.; Cumming, J.N.; Trotter, B.W.; Altman, M.D.; Buevich, A.V.; Cash, B.; et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 2020, 369, eaba6098. [Google Scholar] [CrossRef] [PubMed]
  77. Ramanjulu, J.M.; Pesiridis, G.S.; Yang, J.; Concha, N.; Singhaus, R.; Zhang, S.Y.; Tran, J.L.; Moore, P.; Lehmann, S.; Eberl, H.C.; et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 2018, 564, 439–443. [Google Scholar] [CrossRef] [PubMed]
  78. Pratt, C.B.; Relling, M.V.; Meyer, W.H.; Douglass, E.C.; Kellie, S.J.; Avery, L. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am. J. Clin. Oncol. 1991, 14, 483–486. [Google Scholar] [CrossRef] [PubMed]
  79. Zhang, Z.; Zhou, H.; Ouyang, X.; Dong, Y.; Sarapultsev, A.; Luo, S.; Hu, D. Multifaceted functions of STING in human health and disease: From molecular mechanism to targeted strategy. Signal Transduct. Target. Ther. 2022, 7, 394. [Google Scholar] [CrossRef]
  80. Chien, H.J.; Ying, T.H.; Hsieh, S.C.; Lin, C.L.; Yu, Y.L.; Kao, S.H.; Hsieh, Y.H. alpha-Mangostin attenuates stemness and enhances cisplatin-induced cell death in cervical cancer stem-like cells through induction of mitochondrial-mediated apoptosis. J. Cell. Physiol. 2020, 235, 5590–5601. [Google Scholar] [CrossRef]
  81. Jo, M.K.; Moon, C.M.; Kim, E.J.; Kwon, J.H.; Fei, X.; Kim, S.E.; Jung, S.A.; Kim, M.; Mun, Y.C.; Ahn, Y.H.; et al. Suppressive effect of alpha-mangostin for cancer stem cells in colorectal cancer via the Notch pathway. BMC Cancer 2022, 22, 341. [Google Scholar] [CrossRef] [PubMed]
  82. Jin, S.; Guo, Y.; Wang, X. Development of platinum complexes for tumor chemoimmunotherapy. Chemistry 2024, 30, e202302948. [Google Scholar] [CrossRef] [PubMed]
  83. Liu, J.; Liu, C.; Ma, Y.; Pan, X.; Chu, R.; Yao, S.; Chen, J.; Liu, C.; Chen, Z.; Sheng, C.; et al. STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs). Cancer Lett. 2024, 588, 216700. [Google Scholar] [CrossRef] [PubMed]
  84. Ling, Y.Y.; Xia, X.Y.; Hao, L.; Wang, W.J.; Zhang, H.; Liu, L.Y.; Liu, W.; Li, Z.Y.; Tan, C.P.; Mao, Z.W. Simultaneous photoactivation of cGAS-STING pathway and pyroptosis by platinum(II) triphenylamine complexes for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 2022, 61, e202210988. [Google Scholar] [CrossRef] [PubMed]
  85. Fan, R.; Lin, R.; Zhang, S.; Deng, A.; Hai, Y.; Zhuang, J.; Liu, Y.; Cheng, M.; Wei, G. Novel Pt(IV) complex OAP2 induces STING activation and pyroptosis via mitochondrial membrane remodeling for synergistic chemo-immunotherapy. Acta Pharm. Sin. B 2024, 14, 1742–1758. [Google Scholar] [CrossRef] [PubMed]
  86. Zhang, S.; Song, D.; Yu, W.; Li, J.; Wang, X.; Li, Y.; Zhao, Z.; Xue, Q.; Zhao, J.; Li, J.P.; et al. Combining cisplatin and a STING agonist into one molecule for metalloimmunotherapy of cancer. Natl. Sci. Rev. 2024, 11, nwae020. [Google Scholar] [CrossRef] [PubMed]
  87. Li, F.; Wen, Z.; Wu, C.; Yang, Z.; Wang, Z.; Diao, W.; Chen, D.; Xu, Z.; Lu, Y.; Liu, W. Simultaneous activation of immunogenic cell death and cGAS-STING pathway by liver- and mitochondria-targeted gold(I) complexes for chemoimmunotherapy of hepatocellular carcinoma. J. Med. Chem. 2024, 67, 1982–2003. [Google Scholar] [CrossRef]
  88. Zheng, Y.; Chen, X.X.; Zhang, D.Y.; Wang, W.J.; Peng, K.; Li, Z.Y.; Mao, Z.W.; Tan, C.P. Activation of the cGAS-STING pathway by a mitochondrial DNA-targeted emissive rhodium(iii) metallointercalator. Chem. Sci. 2023, 14, 6890–6903. [Google Scholar] [CrossRef]
  89. Wang, C.G.; Guan, Y.K.; Lv, M.Z.; Zhang, R.; Guo, Z.Y.; Wei, X.M.; Du, X.X.; Yang, J.; Li, T.; Wan, Y.; et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 2018, 48, 675–687.e677. [Google Scholar] [CrossRef]
  90. Zhao, Z.; Ma, Z.; Wang, B.; Guan, Y.; Su, X.D.; Jiang, Z. Mn2+ directly activates cGAS and structural analysis suggests Mn2+ induces a noncanonical catalytic synthesis of 2’3’-cGAMP. Cell Rep. 2020, 32, 108053. [Google Scholar] [CrossRef]
  91. Song, Y.; Liu, Y.; Teo, H.Y.; Hanafi, Z.B.; Mei, Y.; Zhu, Y.; Chua, Y.L.; Lv, M.; Jiang, Z.; Liu, H. Manganese enhances the antitumor function of CD8+ T cells by inducing type I interferon production. Cell Mol. Immunol. 2021, 18, 1571–1574. [Google Scholar] [CrossRef] [PubMed]
  92. Lv, M.Z.; Chen, M.X.; Zhang, R.; Zhang, W.; Wang, C.G.; Zhang, Y.; Wei, X.M.; Guan, Y.K.; Liu, J.J.; Feng, K.C.; et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020, 30, 966–979. [Google Scholar] [CrossRef]
  93. Zhang, S.; Kang, L.; Dai, X.; Chen, J.; Chen, Z.; Wang, M.; Jiang, H.; Wang, X.; Bu, S.; Liu, X.; et al. Manganese induces tumor cell ferroptosis through type-I IFN dependent inhibition of mitochondrial dihydroorotate dehydrogenase. Free Radic. Biol. Med. 2022, 193, 202–212. [Google Scholar] [CrossRef]
  94. Hou, L.; Tian, C.; Yan, Y.; Zhang, L.; Zhang, H.; Zhang, Z. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano 2020, 14, 3927–3940. [Google Scholar] [CrossRef] [PubMed]
  95. Liu, J.; Feng, L.; Wu, Y. Enzymatically synthesised MnO2 nanoparticles for efficient near-infrared photothermal therapy and dual-responsive magnetic resonance imaging. Nanoscale 2021, 13, 11093–11103. [Google Scholar] [CrossRef]
  96. Li, J.; Li, S.; Li, Y.; Yuan, G.; Shen, Y.; Peng, Y.; Kong, L.; Yang, C.; Zhang, Z.; Li, Z. A magnetic resonance nanoprobe with STING activation character collaborates with platinum-based drug for enhanced tumor immunochemotherapy. J. Nanobiotechnol. 2021, 19, 415. [Google Scholar] [CrossRef] [PubMed]
  97. Cai, L.; Wang, Y.; Chen, Y.; Chen, H.; Yang, T.; Zhang, S.; Guo, Z.; Wang, X. Manganese(ii) complexes stimulate antitumor immunity via aggravating DNA damage and activating the cGAS-STING pathway. Chem. Sci. 2023, 14, 4375–4389. [Google Scholar] [CrossRef] [PubMed]
  98. Englinger, B.; Pirker, C.; Heffeter, P.; Terenzi, A.; Kowol, C.R.; Keppler, B.K.; Berger, W. Metal drugs and the anticancer immune response. Chem. Rev. 2019, 119, 1519–1624. [Google Scholar] [CrossRef]
  99. Shen, S.; Lim, G.; You, Z.; Ding, W.; Huang, P.; Ran, C.; Doheny, J.; Caravan, P.; Tate, S.; Hu, K.; et al. Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat. Neurosci. 2017, 20, 1213–1216. [Google Scholar] [CrossRef]
  100. Oun, R.; Moussa, Y.E.; Wheate, N.J. Correction: The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans. 2018, 47, 7848. [Google Scholar] [CrossRef]
  101. Lanvers-Kaminsky, C.; Malath, I.; Deuster, D.; Ciarimboli, G.; Boos, J.; Am Zehnhoff-Dinnesen, A.G. Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity. Clin. Pharmacol. Ther. 2014, 96, 156–157. [Google Scholar] [CrossRef]
  102. Hartmann, J.T.; Lipp, H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889–901. [Google Scholar] [CrossRef]
  103. Pydi, S.P.; Jain, S.; Tung, W.; Cui, Y.; Zhu, L.; Sakamoto, W.; Jain, S.; Abel, B.S.; Skarulis, M.C.; Liu, J.; et al. Adipocyte beta-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. Nat. Commun. 2019, 10, 2936. [Google Scholar] [CrossRef]
  104. Zhang, Y.; Li, M.; Li, L.; Qian, G.; Wang, Y.; Chen, Z.; Liu, J.; Fang, C.; Huang, F.; Guo, D.; et al. beta-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion. Nat. Commun. 2020, 11, 6000. [Google Scholar] [CrossRef]
  105. Vasiliev, Y.M. Chitosan-based vaccine adjuvants: Incomplete characterization complicates preclinical and clinical evaluation. Expert Rev. Vaccines 2015, 14, 37–53. [Google Scholar] [CrossRef] [PubMed]
  106. Carroll, E.C.; Jin, L.; Mori, A.; Munoz-Wolf, N.; Oleszycka, E.; Moran, H.B.T.; Mansouri, S.; McEntee, C.P.; Lambe, E.; Agger, E.M.; et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 2016, 44, 597–608. [Google Scholar] [CrossRef] [PubMed]
  107. Reineke, L.C.; Lloyd, R.E. The stress granule protein G3BP1 recruits protein kinase R to promote multiple innate immune antiviral responses. J. Virol. 2015, 89, 2575–2589. [Google Scholar] [CrossRef]
  108. Watkinson, R.E.; McEwan, W.A.; Tam, J.C.; Vaysburd, M.; James, L.C. TRIM21 Promotes cGAS and RIG-I Sensing of Viral Genomes during Infection by Antibody-Opsonized Virus. PLoS Pathog. 2015, 11, e1005253. [Google Scholar] [CrossRef] [PubMed]
  109. Lian, H.; Wei, J.; Zang, R.; Ye, W.; Yang, Q.; Zhang, X.N.; Chen, Y.D.; Fu, Y.Z.; Hu, M.M.; Lei, C.Q.; et al. Author Correction: ZCCHC3 is a co-sensor of cGAS for dsDNA recognition in innate immune response. Nat. Commun. 2021, 12, 5526. [Google Scholar] [CrossRef]
  110. Liao, C.Y.; Lei, C.Q.; Shu, H.B. PCBP1 modulates the innate immune response by facilitating the binding of cGAS to DNA. Cell Mol. Immunol. 2021, 18, 2334–2343. [Google Scholar] [CrossRef]
  111. Ding, C.; Song, Z.; Shen, A.; Chen, T.; Zhang, A. Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway. Acta Pharm. Sin. B 2020, 10, 2272–2298. [Google Scholar] [CrossRef] [PubMed]
  112. Xie, X.; Ma, G.; Li, X.; Zhao, J.; Zhao, Z.; Zeng, J. Activation of innate immune cGAS-STING pathway contributes to Alzheimer’s pathogenesis in 5xFAD mice. Nat. Aging 2023, 3, 202–212. [Google Scholar] [CrossRef] [PubMed]
  113. Wang, M.M.; Zhao, Y.; Liu, J.; Fan, R.R.; Tang, Y.Q.; Guo, Z.Y.; Li, T. The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases. Acta Pharmacol. Sin. 2024. [CrossRef] [PubMed]
  114. Huang, Y.; Liu, B.; Sinha, S.C.; Amin, S.; Gan, L. Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Mol. Neurodegener. 2023, 18, 79. [Google Scholar] [CrossRef] [PubMed]
  115. Gao, D.; Li, T.; Li, X.D.; Chen, X.; Li, Q.Z.; Wight-Carter, M.; Chen, Z.J. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc. Natl. Acad. Sci. USA 2015, 112, E5699–E5705. [Google Scholar] [CrossRef] [PubMed]
  116. Chu, T.T.; Tu, X.; Yang, K.; Wu, J.; Repa, J.J.; Yan, N. Tonic prime-boost of STING signalling mediates Niemann-Pick disease type C. Nature 2021, 596, 570–575. [Google Scholar] [CrossRef] [PubMed]
  117. Mukai, K.; Konno, H.; Akiba, T.; Uemura, T.; Waguri, S.; Kobayashi, T.; Barber, G.N.; Arai, H.; Taguchi, T. Activation of STING requires palmitoylation at the Golgi. Nat. Commun. 2016, 7, 11932. [Google Scholar] [CrossRef] [PubMed]
  118. Li, Q.; Wu, P.; Du, Q.; Hanif, U.; Hu, H.; Li, K. cGAS-STING, an important signaling pathway in diseases and their therapy. MedComm 2024, 5, e511. [Google Scholar] [CrossRef]
  119. Kang, J.; Wu, J.; Liu, Q.; Wu, X.; Zhao, Y.; Ren, J. Post-translational modifications of STING: A potential therapeutic target. Front. Immunol. 2022, 13, 888147. [Google Scholar] [CrossRef]
  120. Haag, S.M.; Gulen, M.F.; Reymond, L.; Gibelin, A.; Abrami, L.; Decout, A.; Heymann, M.; van der Goot, F.G.; Turcatti, G.; Behrendt, R.; et al. Targeting STING with covalent small-molecule inhibitors. Nature 2018, 559, 269–273. [Google Scholar] [CrossRef]
  121. Hansen, A.L.; Buchan, G.J.; Ruhl, M.; Mukai, K.; Salvatore, S.R.; Ogawa, E.; Andersen, S.D.; Iversen, M.B.; Thielke, A.L.; Gunderstofte, C.; et al. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling. Proc. Natl. Acad. Sci. USA 2018, 115, E7768–E7775. [Google Scholar] [CrossRef] [PubMed]
  122. Su, C.; Cheng, T.; Huang, J.; Zhang, T.; Yin, H. 4-Octyl itaconate restricts STING activation by blocking its palmitoylation. Cell Rep. 2023, 42, 113040. [Google Scholar] [CrossRef]
  123. Humphries, F.; Shmuel-Galia, L.; Jiang, Z.; Zhou, J.Y.; Barasa, L.; Mondal, S.; Wilson, R.; Sultana, N.; Shaffer, S.A.; Ng, S.L.; et al. Targeting STING oligomerization with small-molecule inhibitors. Proc. Natl. Acad. Sci. USA 2023, 120, e2305420120. [Google Scholar] [CrossRef]
  124. Vinogradova, E.V.; Zhang, X.; Remillard, D.; Lazar, D.C.; Suciu, R.M.; Wang, Y.; Bianco, G.; Yamashita, Y.; Crowley, V.M.; Schafroth, M.A.; et al. An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell 2020, 182, 1009–1026.e1029. [Google Scholar] [CrossRef] [PubMed]
  125. Gao, J.; Zheng, M.; Wu, X.; Zhang, H.; Su, H.; Dang, Y.; Ma, M.; Wang, F.; Xu, J.; Chen, L.; et al. CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. EMBO Rep. 2022, 23, e53932. [Google Scholar] [CrossRef] [PubMed]
  126. Abdolmaleky, H.M.; Zhou, J.R. Underlying mechanisms of brain aging and neurodegenerative diseases as potential targets for preventive or therapeutic strategies using phytochemicals. Nutrients 2023, 15, 3456. [Google Scholar] [CrossRef]
  127. Thomson, D.W.; Poeckel, D.; Zinn, N.; Rau, C.; Strohmer, K.; Wagner, A.J.; Graves, A.P.; Perrin, J.; Bantscheff, M.; Duempelfeld, B.; et al. Discovery of GSK8612, a highly selective and potent TBK1 inhibitor. ACS Med. Chem. Lett. 2019, 10, 780–785. [Google Scholar] [CrossRef]
  128. Gao, C.Q.; Chu, Z.Z.; Zhang, D.; Xiao, Y.; Zhou, X.Y.; Wu, J.R.; Yuan, H.; Jiang, Y.C.; Chen, D.; Zhang, J.C.; et al. Serine/threonine kinase TBK1 promotes cholangiocarcinoma progression via direct regulation of beta-catenin. Oncogene 2023, 42, 1492–1507. [Google Scholar] [CrossRef]
  129. Zeng, H.; Gao, Y.; Yu, W.; Liu, J.; Zhong, C.; Su, X.; Wen, S.; Liang, H. Pharmacological inhibition of STING/TBK1 signaling attenuates myeloid fibroblast activation and macrophage to myofibroblast transition in renal fibrosis. Front. Pharmacol. 2022, 13, 940716. [Google Scholar] [CrossRef]
  130. Barasa, L.; Chaudhuri, S.; Zhou, J.Y.; Jiang, Z.; Choudhary, S.; Green, R.M.; Wiggin, E.; Cameron, M.; Humphries, F.; Fitzgerald, K.A.; et al. Development of LB244, an irreversible STING antagonist. J. Am. Chem. Soc. 2023, 145, 20273–20288. [Google Scholar] [CrossRef]
  131. Hong, Z.; Mei, J.; Li, C.; Bai, G.; Maimaiti, M.; Hu, H.; Yu, W.; Sun, L.; Zhang, L.; Cheng, D.; et al. STING inhibitors target the cyclic dinucleotide binding pocket. Proc. Natl. Acad. Sci. USA 2021, 118, e2105465118. [Google Scholar] [CrossRef] [PubMed]
  132. Hall, J.; Brault, A.; Vincent, F.; Weng, S.; Wang, H.; Dumlao, D.; Aulabaugh, A.; Aivazian, D.; Castro, D.; Chen, M.; et al. Discovery of PF-06928215 as a high affinity inhibitor of cGAS enabled by a novel fluorescence polarization assay. PLoS ONE 2017, 12, e0184843. [Google Scholar] [CrossRef] [PubMed]
  133. Padilla-Salinas, R.; Sun, L.; Anderson, R.; Yang, X.; Zhang, S.; Chen, Z.J.; Yin, H. Discovery of small-molecule cyclic GMP-AMP synthase inhibitors. J. Org. Chem. 2020, 85, 1579–1600. [Google Scholar] [CrossRef] [PubMed]
  134. Vincent, J.; Adura, C.; Gao, P.; Luz, A.; Lama, L.; Asano, Y.; Okamoto, R.; Imaeda, T.; Aida, J.; Rothamel, K.; et al. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nat. Commun. 2017, 8, 750. [Google Scholar] [CrossRef] [PubMed]
  135. Lama, L.; Adura, C.; Xie, W.; Tomita, D.; Kamei, T.; Kuryavyi, V.; Gogakos, T.; Steinberg, J.I.; Miller, M.; Ramos-Espiritu, L.; et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat. Commun. 2019, 10, 2261. [Google Scholar] [CrossRef] [PubMed]
  136. Tan, J.; Wu, B.; Chen, T.; Fan, C.; Zhao, J.; Xiong, C.; Feng, C.; Xiao, R.; Ding, C.; Tang, W.; et al. Synthesis and pharmacological evaluation of tetrahydro-gamma-carboline derivatives as potent anti-inflammatory agents targeting cyclic GMP-AMP synthase. J. Med. Chem. 2021, 64, 7667–7690. [Google Scholar] [CrossRef] [PubMed]
  137. Chu, L.; Li, C.; Li, Y.; Yu, Q.; Yu, H.; Li, C.; Meng, W.; Zhu, J.; Wang, Q.; Wang, C.; et al. Perillaldehyde inhibition of cGAS reduces dsDNA-induced interferon response. Front. Immunol. 2021, 12, 655637. [Google Scholar] [CrossRef] [PubMed]
  138. Shim, J.H.; Su, Z.Y.; Chae, J.I.; Kim, D.J.; Zhu, F.; Ma, W.Y.; Bode, A.M.; Yang, C.S.; Dong, Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev. Res. 2010, 3, 670–679. [Google Scholar] [CrossRef]
  139. Liu, Z.S.; Cai, H.; Xue, W.; Wang, M.; Xia, T.; Li, W.J.; Xing, J.Q.; Zhao, M.; Huang, Y.J.; Chen, S.; et al. G3BP1 promotes DNA binding and activation of cGAS. Nat. Immunol. 2019, 20, 18–28. [Google Scholar] [CrossRef]
  140. Dai, J.; Huang, Y.J.; He, X.; Zhao, M.; Wang, X.; Liu, Z.S.; Xue, W.; Cai, H.; Zhan, X.Y.; Huang, S.Y.; et al. Acetylation blocks cGAS activity and inhibits self-DNA-induced autoimmunity. Cell 2019, 176, 1447–1460. [Google Scholar] [CrossRef]
  141. Wang, M.; Sooreshjani, M.A.; Mikek, C.; Opoku-Temeng, C.; Sintim, H.O. Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-beta levels. Future Med. Chem. 2018, 10, 1301–1317. [Google Scholar] [CrossRef] [PubMed]
  142. An, J.; Woodward, J.J.; Sasaki, T.; Minie, M.; Elkon, K.B. Cutting edge: Antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 2015, 194, 4089–4093. [Google Scholar] [CrossRef] [PubMed]
  143. Meric-Bernstam, F.; Sandhu, S.K.; Hamid, O.; Spreafico, A.; Kasper, S.; Dummer, R.; Shimizu, T.; Steeghs, N.; Lewis, N.; Talluto, C.C.; et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J. Clin. Oncol. 2019, 37, 2507. [Google Scholar] [CrossRef]
  144. Harrington, K.J.; Brody, J.; Ingham, M.; Strauss, J.; Cemerski, S.; Wang, M.; Tse, A.; Khilnani, A.; Marabelle, A.; Golan, T. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann. Oncol. 2018, 29, viii712. [Google Scholar] [CrossRef]
  145. Irvine, D.J.; Aung, A.; Silva, M. Controlling timing and location in vaccines. Adv. Drug. Deliv. Rev. 2020, 158, 91–115. [Google Scholar] [CrossRef] [PubMed]
  146. Woo, S.R.; Corrales, L.; Gajewski, T.F. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015, 36, 250–256. [Google Scholar] [CrossRef] [PubMed]
  147. Wu, J.; Dobbs, N.; Yang, K.; Yan, N. Interferon-ondependent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 2020, 53, 115–126.e115. [Google Scholar] [CrossRef] [PubMed]
  148. Le, R.Q.; Li, L.; Yuan, W.; Shord, S.S.; Nie, L.; Habtemariam, B.A.; Przepiorka, D.; Farrell, A.T.; Pazdur, R. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-Induced severe or life-threatening cytokine release syndrome. Oncologist 2018, 23, 943–947. [Google Scholar] [CrossRef]
  149. Xue, Y.; Bai, H.; Peng, B.; Fang, B.; Baell, J.; Li, L.; Huang, W.; Voelcker, N.H. Stimulus-cleavable chemistry in the field of controlled drug delivery. Chem. Soc. Rev. 2021, 50, 4872–4931. [Google Scholar] [CrossRef]
  150. Garland, K.M.; Sheehy, T.L.; Wilson, J.T. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem. Rev. 2022, 122, 5977–6039. [Google Scholar] [CrossRef]
Molecules 29 03121 g001
Figure 1. The action of agonist or inhibitor on the cGAS-STING pathway. dsDNA binds to cGAS and activates cGAS, leading to the synthesis of cGAMP. cGAMP binds to the STING located on the ER, inducing conformational changes and oligomerization of STING. The STING oligomers release from the ER and translocate to the Golgi apparatus, where they recruit TBK1 and IKK kinases. Phosphorylated IRF3 and IκBα form functional signalosomes and translocate into the nucleus to induce the expression of IFNs and immune-stimulated genes. The cGAS-STING agonist or inhibitor promotes or impedes these processes.
Figure 1. The action of agonist or inhibitor on the cGAS-STING pathway. dsDNA binds to cGAS and activates cGAS, leading to the synthesis of cGAMP. cGAMP binds to the STING located on the ER, inducing conformational changes and oligomerization of STING. The STING oligomers release from the ER and translocate to the Golgi apparatus, where they recruit TBK1 and IKK kinases. Phosphorylated IRF3 and IκBα form functional signalosomes and translocate into the nucleus to induce the expression of IFNs and immune-stimulated genes. The cGAS-STING agonist or inhibitor promotes or impedes these processes.
Molecules 29 03121 g001
Molecules 29 03121 g002
Figure 2. Actions of different cGAS-STING agonists. cGAS-STING agonists enhance the release of IFNs and maturation of DCs by activating the cGAS-STING pathway, leading to the activation of T cells and NK cells, and ultimately to the killing of tumor cells.
Figure 2. Actions of different cGAS-STING agonists. cGAS-STING agonists enhance the release of IFNs and maturation of DCs by activating the cGAS-STING pathway, leading to the activation of T cells and NK cells, and ultimately to the killing of tumor cells.
Molecules 29 03121 g002
Molecules 29 03121 g003
Figure 3. (A) Overall structure of STING C-terminal domain bound to the cGAS product. STING forms a dimer and is colored in yellow and cyan for each molecule, respectively, in the right panel, and the 2′3′-cGAMP molecule is indicated. (B) A detailed view of the cGAS product within the STING structure. cGAMP binding at a deeper pocket drags the STING dimers (blue) closer to each other, compared to c-di-GMP-bound STING (PDB ID code 4F9G, gray). Structures are adapted with permission from Ref. [53]. Copyright 2013, Elsevier Inc.
Figure 3. (A) Overall structure of STING C-terminal domain bound to the cGAS product. STING forms a dimer and is colored in yellow and cyan for each molecule, respectively, in the right panel, and the 2′3′-cGAMP molecule is indicated. (B) A detailed view of the cGAS product within the STING structure. cGAMP binding at a deeper pocket drags the STING dimers (blue) closer to each other, compared to c-di-GMP-bound STING (PDB ID code 4F9G, gray). Structures are adapted with permission from Ref. [53]. Copyright 2013, Elsevier Inc.
Molecules 29 03121 g003
Molecules 29 03121 g004
Figure 4. Structures of CDN-type STING agonists.
Figure 4. Structures of CDN-type STING agonists.
Molecules 29 03121 g004
Molecules 29 03121 g005
Figure 5. Structures of non-CDN-type STING agonists.
Figure 5. Structures of non-CDN-type STING agonists.
Molecules 29 03121 g005
Molecules 29 03121 g006
Figure 6. Structures of representative metal complexes as cGAS-STING agonists.
Figure 6. Structures of representative metal complexes as cGAS-STING agonists.
Molecules 29 03121 g006
Molecules 29 03121 g007
Figure 7. Proposed mechanism of action for manganese complexes 16 and 17 [97].
Figure 7. Proposed mechanism of action for manganese complexes 16 and 17 [97].
Molecules 29 03121 g007
Molecules 29 03121 g008
Figure 8. The crystal structures of cGAS dimer with dsDNA (PDB ID: 6ct9) and STING with 2′,3′-cGAMP (PDB ID: 4ef4); cGAS inhibitors directly inhibit cGAS or cGAS binding to dsDNA; STING inhibitors inhibit STING palmitoylation, CDN pocket, or direct transplanting of TBK1; and diseases associated with the overactivation of cGAS-STING pathway.
Figure 8. The crystal structures of cGAS dimer with dsDNA (PDB ID: 6ct9) and STING with 2′,3′-cGAMP (PDB ID: 4ef4); cGAS inhibitors directly inhibit cGAS or cGAS binding to dsDNA; STING inhibitors inhibit STING palmitoylation, CDN pocket, or direct transplanting of TBK1; and diseases associated with the overactivation of cGAS-STING pathway.
Molecules 29 03121 g008
Molecules 29 03121 g009
Figure 9. Structures of STING inhibitors.
Figure 9. Structures of STING inhibitors.
Molecules 29 03121 g009
Molecules 29 03121 g010
Figure 10. Structures of cGAS inhibitors.
Figure 10. Structures of cGAS inhibitors.
Molecules 29 03121 g010
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yu, X.; Cai, L.; Yao, J.; Li, C.; Wang, X. Agonists and Inhibitors of the cGAS-STING Pathway. Molecules 2024, 29, 3121. https://doi.org/10.3390/molecules29133121

AMA Style

Yu X, Cai L, Yao J, Li C, Wang X. Agonists and Inhibitors of the cGAS-STING Pathway. Molecules. 2024; 29(13):3121. https://doi.org/10.3390/molecules29133121

Chicago/Turabian Style

Yu, Xiaoxuan, Linxiang Cai, Jingyue Yao, Cenming Li, and Xiaoyong Wang. 2024. "Agonists and Inhibitors of the cGAS-STING Pathway" Molecules 29, no. 13: 3121. https://doi.org/10.3390/molecules29133121

Article Metrics

Back to TopTop